AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1725027
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of ramipril
Trial: 6440793
Drug: Ro 15-1788
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15-1788 30 mg (2 tablets)
Trial: 31027098
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with methylene blue (MB) at 0.005% concentration and low intensity laser irradiation (λ = 660 nm, 9J per point, radiant exposure of 318 J/cm)
Trial: 26864411
Drug: Dose-equivalent occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-equivalent occupational therapy (DEUCC)
Trial: 26864411
Drug: Monitoring-only occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring-only occupational therapy (UCC)
Trial: 24499460
Drug: Respiratory therapy
RxNorm normalized name: respiratory therapy supplies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory therapy (Control)
Trial: 18443390
Drug: Parent-child cognitive
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-child cognitive behavioral therapy (CBT)
Trial: 16110025
Drug: DCF (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5)
Trial: 16110025
Drug: DC (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1)
Trial: 9649697
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream applied for 10 minutes
Trial: 9649697
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream applied for 20 minutes
Trial: 8834128
Drug: Chronic home
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic home oxygen therapy (mean 16.4 h/day) with standard pharmacological treatment (prednisone 10‐15 mg/day) for 4 years
Trial: 8834128
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatment (prednisone 10‐15 mg/day) alone for 4 years
Trial: 2473061
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy and RT with cytokines
Trial: 31121331
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of a mixture of 0.5ml hyaluronic acid and 0.5ml corticosteroid
Trial: 31121331
Drug: Arthrocentesis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis with Ringer solution
Trial: 23378346
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid (prednisolone) administered daily for 3 consecutive days
Trial: 23378346
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline solution) administered daily for 3 consecutive days
Trial: 23378346
Drug: Intratympanic steroid
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic steroid (prednisolone)
Trial: 16808624
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (internal dose median 168 mSv, external dose median 280 mSv)
Trial: 16808624
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (internal dose negligible, external dose median 22 mSv)
Trial: 16808624
Drug: High-dose group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group, Low-dose group, Control group
Trial: 15526507
Drug: Rovamycine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovamycine 12 days 4.5 MUI iv/day as add-on therapy
Trial: 15526507
Drug: Rovamycine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovamycine 12 days 4.5 MUI iv/day followed by 6 MUI/day per os for another 12 days add-on treatment
Trial: 6699425
Drug: Topical 8-methoxypsoralen
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 8-methoxypsoralen (8-MOP) with small doses of UVA irradiation
Trial: 31791376
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line antihypertensive treatment
Trial: 27222759
Drug: Passive-active distraction
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive-active distraction (combination of both techniques)
Trial: 21384431
Drug: Memantine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine treatment in mild AD patients
Trial: 21384431
Drug: Memantine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine treatment in moderate AD patients
Trial: 17851346
Drug: Rectal irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal irrigation
Trial: 1693065
Drug: Inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine pranobex (3 g/day)
Trial: 30922128
Drug: Early inhaled
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early inhaled bronchodilators
Trial: 30922128
Drug: No bronchodilators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bronchodilators
Trial: 23615131
Drug: PEG IFNα‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG IFNα‐2a (135 μg once weekly) plus lamivudine (100 mg daily)
Trial: 23615131
Drug: PEG IFNα‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG IFNα‐2a (135 μg once weekly) plus adefovir (10 mg daily)
Trial: 17685744
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus ziprasidone 80 mg/day
Trial: 17685744
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus ziprasidone 160 mg/day
Trial: 15164103
Drug: Nutrient supplementation
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient supplementation containing omega-3 fatty acids (1.4 g EPA, 0.211 g DHA, 0.5 g GLA) and micronutrients
Trial: 11477493
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (0.15 IU/kg body weight/week)
Trial: 2956040
Drug: semisynthetic human
RxNorm normalized name: INSULIN,NPH,HUMAN/SEMISYNTHETIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semisynthetic human NPH insulin
Trial: 2956040
Drug: porcine NPH
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: porcine NPH insulin
Trial: 12601301
Drug: Gemcitabine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (300 mg/m2), Paclitaxel (70 mg/m2), Carboplatin (AUC 5)
Trial: 11713946
Drug: Lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg daily (LAN 15)
Trial: 11713946
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg daily (LAN 30)
Trial: 11713946
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice a day (RAN 150)
Trial: 9165379
Drug: Amisulpride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50 mg/daily)
Trial: 9165379
Drug: Imipramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (100 mg/daily)
Trial: 7705093
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to 150 mg + misoprostol 600 micrograms (Group 1)
Trial: 7705093
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg followed by 25 mg every 12 hours up to 150 mg + PG05 1 mg vaginal suppository (Group 2)
Trial: 7712903
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg + misoprostol 600 micrograms (Group 3)
Trial: 30439866
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib (IVPA group)
Trial: 28189475
Drug: Alprostadil treatment
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil treatment twice daily for 4 weeks
Trial: 28189475
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment twice daily for 4 weeks
Trial: 25183687
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg once daily) plus Indacaterol (150 μg once daily)
Trial: 25183687
Drug: Advair(®) (50/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advair(®) (50/250 μg twice daily)
Trial: 23212243
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (rt‐PA) for the treatment of acute stroke
Trial: 21255498
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) oxygen therapy
Trial: 21255498
Drug: Standard high-flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard high-flow face mask (HFFM) oxygen therapy
Trial: 9167811
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (rest and gradual return to activity)
Trial: 30251100
Drug: Meniscal repair
RxNorm normalized name: Sus scrofa meniscus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meniscal repair concurrent with ACL reconstruction
Trial: 28264824
Drug: Supervised 1-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised 1-hour aerobic and resistance exercise (twice per week for 18 weeks)
Trial: 21693037
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day) + Norethisterone acetate (2.5 mg/day)
Trial: 21693037
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day) + Triptorelin (11.25 mg every 3 months)
Trial: 14615107
Drug: Diuretics or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics or beta blockers
Trial: 10668157
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone (50 mg/day)
Trial: 10668157
Drug: Vaginal gel
RxNorm normalized name: VAGINAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal gel progesterone (90 mg/day)
Trial: 8684199
Drug: Enoxaparin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (40 mg, once daily for 21 days)
Trial: 1832883
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid rescue dose of less than 15 mg/m2
Trial: 1832883
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid rescue dose of 15 mg/m2 (75 mg/m2)
Trial: 7049346
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (Cy) alone
Trial: 7049346
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (Cy) + prednisolone (Pred) 100 mg/m2 orally daily for two days
Trial: 7049346
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (Cy) alone in small cell carcinoma
Trial: 7049346
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (Cy) alone in non-small cell carcinoma
Trial: 27505987
Drug: 2 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mmol/L ferrous sulfate
Trial: 27505987
Drug: 2 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mmol/L ferrous fumarate
Trial: 24999004
Drug: Caffeine (CAF),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF), 3 mg/kg, 45 min prior to PT
Trial: 24999004
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate (SB), 0.3 g/kg, 75 min prior to PT
Trial: 17558830
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg) infusions every two weeks for six weeks, then every four weeks
Trial: 14726934
Drug: Recombinant erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant erythropoietin (rEpo) administration starting in the first week of life
Trial: 30412479
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (UD) for 2 weeks
Trial: 28444084
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (35mg capsules, 70mg/day, for 16 weeks)
Trial: 28444084
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, twice daily)
Trial: 25223231
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) 250 mL (3 times at 12-hr intervals)
Trial: 25223231
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 400 mg (12 hr before tilidine administration)
Trial: 25223231
Drug: Tilidine 100
RxNorm normalized name: tilidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilidine 100 mg solution p.o.
Trial: 21272194
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy prescribed to patients with diabetes
Trial: 21272194
Drug: Failure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failure to intensify therapy
Trial: 19428005
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (200 microg every 6 hours)
Trial: 17160912
Drug: Ruboxistaurin (PKC-β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin (PKC-β isoform-selective inhibitor)
Trial: 11037083
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) - six 30 min sessions over 3 months
Trial: 8900907
Drug: Amoxycillin 500
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 500 mg four times daily plus ranitidine 300 mg four times daily
Trial: 8900907
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice daily plus ranitidine 300 mg twice daily
Trial: 8900907
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg four times daily plus ranitidine 300 mg twice daily
Trial: 8900907
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg four times daily plus ranitidine 300 mg four times daily
Trial: 1992998
Drug: Intravenous IgG
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous IgG (0.4 g/kg, repeated on days +1 and +5)
Trial: 6391389
Drug: Antibiotics (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (Group A)
Trial: 6391389
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (Group B)
Trial: 30425012
Drug: Therapeutic Touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Touch (4 treatments on 4 consecutive days)
Trial: 19581264
Drug: All hormone-treated
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hormone-treated subjects
Trial: 19581264
Drug: Combined 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 4 thyroid hormone treatment arms
Trial: 17095411
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of caffeine (Experiment A)
Trial: 17095411
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of caffeine (Experiment B)
Trial: 11422089
Drug: Intravenous metamizol
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metamizol
Trial: 14722642
Drug: Intravenous propacetamol
RxNorm normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propacetamol
Trial: 2840630
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) during intensive chemotherapy and irradiation
Trial: 2840630
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) for severe varicella-zoster virus infections
Trial: 2840630
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) for bacterial infections
Trial: 29171129
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance tests (OGTTs) at diagnosis
Trial: 28302155
Drug: Topical aganirsen
RxNorm normalized name: Aganirsen
DrugBank: Aganirsen (DB15369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aganirsen
Trial: 14692209
Drug: Gas chromatography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gas chromatography (GC) method for detecting volatile sulfur compounds
Trial: 9197826
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (ALA) 30%
Trial: 9197826
Drug: Topical 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolevulinic acid (ALA) 10%, 20%, or 30%
Trial: 9197826
Drug: Vehicle and
RxNorm normalized name: Vehicle and emulsifier patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle and light treatment (Control)
Trial: 7018846
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral pentaerythritol tetranitrate (PETN)
Trial: 28560554
Drug: Continuous postoperative
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous postoperative local analgesia with ropivacaine 5 mg/ml
Trial: 19699738
Drug: Rectal enemas
RxNorm normalized name: Enema
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal enemas in addition to conventional therapy
Trial: 17009844
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Vagimid Dragees) 500 mg metronidazole
Trial: 17009844
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation 500 mg metronidazole
Trial: 12707123
Drug: Pancuronium (0.08-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.08-0.1 mg/kg)
Trial: 12707123
Drug: Rocuronium (0.6-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.6-0.8 mg/kg)
Trial: 2301321
Drug: Treatment diet
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment diet (electrolyte solution then dilute soy formula, dilute cow's milk formula, or undiluted soy formula)
Trial: 6951573
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment with comprehensive, assertive and prolonged follow‐up treatment backed by a 24‐hour crisis service.
Trial: 31813230
Drug: Kava (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava (120 mg of kavalactones twice/day)
Trial: 27893182
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (300 mg)
Trial: 27893182
Drug: Rivaroxaban (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (40 mg)